Optinose (NASDAQ: OPTN) is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists.

The innovative mechanism of action of the Optinose Exhalation Delivery system (EDS) technology is designed to enable broad, consistent drug delivery high and deep in the nasal passages, leveraging the mucosal surfaces as a potential target for the treatment of local, systemic, and central nervous system diseases.

Please visit the Optinose website to learn more.